Oklahoma Heart Institute joins national cardiovascular trials, uses Supira pVAD in SUPPORT II study
ARDT•Oklahoma Heart Institute joins national cardiovascular trials
Oklahoma Heart Institute, part of Hillcrest HealthCare System, became the first US site to use Supira’s next-generation pVAD in the SUPPORT II trial.
The institute is now the only site in Oklahoma and the surrounding region participating in several national cardiovascular trials, expanding access to investigational devices.
OHI was the leading global enroller in the ENCIRCLE Trial supporting 2025 FDA clearance of Edwards’ SAPIEN M3 TMVR system; it now offers the therapy locally.
